The medical TGIB has a robust clinical program for treatment of patients with advanced thoracic and GI cancers who have failed standard therapies. The thoracic team is conducting innovative studies for patients with non-small cell lung cancer, small cell lung cancer, malignant mesothelioma and thymic cancers. These include use of novel treatments developed by scientists at the NCI. A major focus of our team is the development of drugs targeting the tumor antigen, mesothelin that is highly expressed in many cancers. We are using a monoclonal antibody- MORAb-009, an immunotoxin -SS1P, an antibody drug conjugate- BAY 94-9343 and a mesothelin vaccine- CRS-207 to treat these cancers. In addition, we are conducting clinical trials using immunotherapy agents including immune checkpoint inhibitors to treat patients with thoracic cancers who have failed standard treatments. The TGIB is also conducting studies for treatment of gastrointestinal cancers with a special emphasis on liver cancer. Investigators within the TGIB have established a robust program for treatment of patients with liver cancer including use of immunotherapy agents either alone or in combination with radiation therapy or locally ablative therapies for liver cancer. The gastrointestinal group is also conducting clinical trials of novel agents for treatment of pancreatic cancer.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Clinical Support Services Intramural Research (ZID)
Project #
1ZIDBC011540-02
Application #
9154379
Study Section
Project Start
Project End
Budget Start
Budget End
Support Year
2
Fiscal Year
2015
Total Cost
Indirect Cost
Name
Basic Sciences
Department
Type
DUNS #
City
State
Country
Zip Code
An, Julie Y; Kim, David; Tanakchi, Sally et al. (2017) Clinical Features and Outcomes of Tunica Vaginalis Mesothelioma: A Case Series From the National Institutes of Health. Clin Genitourin Cancer 15:e871-e875
Lindenberg, Liza; Thomas, Anish; Adler, Stephen et al. (2015) Safety and biodistribution of 111In-amatuximab in patients with mesothelin expressing cancers using single photon emission computed tomography-computed tomography (SPECT-CT) imaging. Oncotarget 6:4496-504
Kalra, Neetu; Zhang, Jingli; Thomas, Anish et al. (2015) Mesothelioma patient derived tumor xenografts with defined BAP1 mutations that mimic the molecular characteristics of human malignant mesothelioma. BMC Cancer 15:376
Thomas, Anish; Chen, Yuanbin; Steinberg, Seth M et al. (2015) High mesothelin expression in advanced lung adenocarcinoma is associated with KRAS mutations and a poor prognosis. Oncotarget 6:11694-703
Hassan, Raffit; Kindler, Hedy L; Jahan, Thierry et al. (2014) Phase II clinical trial of amatuximab, a chimeric antimesothelin antibody with pemetrexed and cisplatin in advanced unresectable pleural mesothelioma. Clin Cancer Res 20:5927-36
Keenan, Bridget P; Saenger, Yvonne; Kafrouni, Michel I et al. (2014) A Listeria vaccine and depletion of T-regulatory cells activate immunity against early stage pancreatic intraepithelial neoplasms and prolong survival of mice. Gastroenterology 146:1784-94.e6
Miller, Andrew C; Miettinen, Markku; Schrump, David S et al. (2014) Malignant mesothelioma and central nervous system metastases. Report of two cases, pooled analysis, and systematic review. Ann Am Thorac Soc 11:1075-81
Chen, Yuanbin; Gharwan, Helen; Thomas, Anish (2014) Novel biologic therapies for thymic epithelial tumors. Front Oncol 4:103
Jakopovic, Marko; Thomas, Anish; Lopez-Chavez, Ariel (2014) From platinum compounds to targeted therapies in advanced thoracic malignancies. Anticancer Res 34:477-82
Hassan, Raffit; Sharon, Elad; Thomas, Anish et al. (2014) Phase 1 study of the antimesothelin immunotoxin SS1P in combination with pemetrexed and cisplatin for front-line therapy of pleural mesothelioma and correlation of tumor response with serum mesothelin, megakaryocyte potentiating factor, and cancer antigen Cancer 120:3311-9

Showing the most recent 10 out of 26 publications